Form 4: KalVista CMO Sells Shares for Tax Obligations

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, acquired shares through RSU conversions and subsequently sold a portion to cover tax withholding obligations.

Summary

• Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, Inc. (KALV), reported changes in beneficial ownership.
• On February 21, 2026, Audhya acquired 6,250 shares of Common Stock through the conversion of Restricted Stock Units (RSUs).
• On February 22, 2026, Audhya acquired an additional 5,000 shares of Common Stock through RSU conversion.
• Following these acquisitions, Audhya beneficially owned 144,337 shares of Common Stock.
• On February 23, 2026, Audhya disposed of 5,354 shares of Common Stock at a weighted average price of $15.5668 per share.
• This sale was a 'sell to cover' transaction, specifically to satisfy tax withholding obligations related to the vesting and settlement of RSUs, and was not a discretionary transaction.
• After the sale, Audhya's beneficial ownership of Common Stock was 138,983 shares.
• Audhya also holds 45,000 Restricted Stock Units (RSUs) as of February 22, 2026, which represent a contingent right to receive one share of Common Stock each upon settlement for no consideration.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there is an insider sale, it is non-discretionary and for tax purposes, which is routine. The underlying RSU vesting indicates continued executive incentive alignment.

Positives

• The vesting and settlement of Restricted Stock Units (RSUs) indicate the continued alignment of management's interests with shareholders through equity compensation.
• The acquisition of shares through RSU conversions increases the Chief Medical Officer's direct equity stake in the company, demonstrating ongoing commitment.

Negatives

• The sale of 5,354 shares by an insider, even for tax purposes, slightly increases the public float and could be perceived as a minor reduction in direct ownership, though it is explicitly non-discretionary.

Risks

• The vesting of Restricted Stock Units is subject to continued service through each vesting date, meaning the reporting person would forfeit unvested units if employment ceases.

Future Outlook

Restricted Stock Units (RSUs) vest at a rate of 1/16th of the total number of shares subject to the RSU on each quarterly anniversary of the Vesting Commencement Date, contingent upon continued service through each vesting date.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, particularly 'sell to cover' transactions for tax obligations related to equity compensation, are routine occurrences in publicly traded companies. These transactions are a standard part of executive compensation structures and typically do not signal a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: A very minor, negligible increase in the public float due to the 'sell to cover' transaction. No significant impact on company valuation or strategy is implied.
• Reporting Person (Paul K. Audhya): The transactions facilitate the realization of equity compensation and cover associated tax liabilities.

Next Steps

• Continued vesting of remaining Restricted Stock Units on a quarterly basis, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation and tax obligations. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The 'sell to cover' is non-discretionary and expected. Therefore, a 'hold' recommendation is appropriate as the filing does not alter the fundamental investment thesis for KalVista Pharmaceuticals.

Keywords

KalVista Pharmaceuticals, KALV, Form 4, Insider Trading, Restricted Stock Units, RSU, Equity Compensation, Chief Medical Officer, Paul K. Audhya, Sell to Cover, Beneficial Ownership